COMMUNIQUÉS West-GlobeNewswire

Novo Nordisk's sales increased by 6% in Danish kroner and by 10% at constant exchange rates to DKK 309.1 billion in 2025
03/02/2026
Bagsværd, Denmark 3 February 2026 - Financial report for the period 1 January 2025 to 31 December 2025 Operating profit decreased by 1% in Danish kroner and increased by 6% at constant exchange rates (CER) to DKK 127.7 [...]
Novo Nordisk releases 2026 sales and operating profit outlook
03/02/2026
Bagsværd, Denmark, 3 February 2026 – Novo Nordisk today announced sales and operating profit growth at constant exchange rates (CER) for 2025 and released the 2026 full-year sales and operating profit outlook at CER. [...]
MediGlow Utility (MGU) Releases a Technical Exploration Framework for Digital Identity and Privacy Protection
03/02/2026
MediGlow Utility (MGU) Proposes a Technical Practice Direction for Medical Data Management Based on Blockchain Technology New York, NY, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Recently, MediGlow Utility (MGU) announced the [...]
RESTEM Announces First Patient Dosed in the Phase 2/3 IIMPACT Study of Restem-L in Idiopathic Inflammatory Myopathy
03/02/2026
Initiation of the IIMPACT study follows promising Phase 1 results where Restem-L demonstrated clinically meaningful efficacy and a significant reduction in steroid use within 6 months in Idiopathic Inflammatory Myopathy [...]
Neomorph Announces First Patient Dosed in Phase 1/2 Trial Evaluating NEO-811 For the Treatment of Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
03/02/2026
Initiation of trial marks first-in-human milestone for Neomorph’s novel molecular glue degrader platform SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Neomorph, Inc. , a biotechnology company pioneering molecular glue [...]
Socrates Health Solutions Announces Advances in Proprietary Non-Invasive Glucose Monitoring Technology; Shareholders Include NFL Players Association and OneTeam Partners
03/02/2026
DALLAS, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Socrates Health Solutions (“Socrates”), advancing a purpose-led mission to pursue a better feedback loop for health issues spanning diabetes management, broader health [...]
Byonyks X1: Revolutionizing Dialysis - Now FDA Cleared and Planning to start Patients in the U.S.
03/02/2026
A major regulatory milestone positioning Byonyks as a new entrant in home-based renal care CHICAGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Byonyks, headquartered in Chicago, Illinois, has received U.S. FDA 510(k) clearance [...]
Berry Street Named to 2026 New York Digital Health 100 List
03/02/2026
Digital Health New York recognizes nutrition therapy platform’s innovative approach to evidence-based nutrition care NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Berry Street , a nutrition therapy platform, today [...]
Beghou Names Meredith Ressi as President and Chief Growth Officer
03/02/2026
Appointment reflects Beghou’s focus on scaling intelligently with integrated teams and technology to support clients throughout their commercialization journey EVANSTON, Ill., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Beghou , [...]
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/02/2026
MONTREAL and CHARLOTTE, N.C., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a [...]
Enovis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
03/02/2026
Dallas TX, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that management will participate in the BTIG 13th Annual MedTech, [...]
Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer
03/02/2026
Mr. Pujols brings more than 30 years of technical operations expertise to role, scaling commercial manufacturing for CAR T-cell therapies and complex biologics, as Kyverna advances towards launch of miv-cel EMERYVILLE, [...]
Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update
03/02/2026
April 10, 2026 Target Action Date for RP1 in Advanced Melanoma WOBURN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of [...]
aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis
03/02/2026
Meeting with the FDA to review the results from the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis is scheduled for mid-April 2026. SAN DIEGO, Feb. 03, 2026 (GLOBE [...]
IN8bio to Present at Upcoming Investor and Scientific Conferences in February
03/02/2026
NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc . (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ ) T cell therapies for cancer and autoimmune diseases, today [...]
Mesa Labs Announces Third Quarter Results
03/02/2026
LAKEWOOD, Colo., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa” or “the Company”), a global leader in the design and manufacture of life science tools and critical quality control [...]
Amicus Therapeutics Presents New Long-term Data for both Galafold® (migalastat) and POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at the 22nd Annual WORLDSymposium™ 2026
03/02/2026
PRINCETON, N.J., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced the presentation of new data from clinical and real-world studies of Galafold ® (migalastat) in Fabry disease and [...]
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
03/02/2026
BOSTON and LONDON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today [...]
Byonyks X1: Revolutinizing Dialysis - Now FDA Cleared and Planning to start Patients in the U.S.
03/02/2026
A major regulatory milestone positioning Byonyks as a new entrant in home-based renal care CHICAGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Byonyks, headquartered in Chicago, Illinois, has received U.S. FDA 510(k) clearance [...]

Pages